Drug Profile
Zirconium 89 DFO MSTP 2109A - Memorial Sloan Kettering Cancer Center
Alternative Names: 89Zr-DFO-MSTP2109A; Zirconium-89 DFO MSTP 2109ALatest Information Update: 18 May 2023
Price :
$50
*
At a glance
- Originator Memorial Sloan-Kettering Cancer Center
- Developer Genentech; Memorial Sloan-Kettering Cancer Center
- Class Antibody diagnostics; Drug conjugates; Immunoconjugates; Radiopharmaceutical diagnostics
- Mechanism of Action Positron-emission tomography enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Prostate cancer
Most Recent Events
- 02 May 2023 Memorial Sloan Kettering Cancer Center and Genentech complete a phase I/II trial for Prostate cancer (Diagnosis) in USA (NCT01774071)
- 18 Feb 2016 Phase-I/II development is ongoing in USA
- 18 Aug 2015 Memorial Sloan Kettering Cancer Center and Genentech complete enrolment in a phase I/II trial for Prostate cancer (Diagnosis) in USA (NCT01774071)